Carcinoma of the prostate: the treatment of bone metastases by radioactive phosphorus (32P).
The administration of radioactive phosphorus and testosterone benefitted two-thirds of thirty patients with prostate cancer treated. Subjective relief of bone pain occurred in 73% of cases and measurable objective improvement occurred in 50%. Hematopoietic depression occurred in 30% of the patients necessitating readmission to hospital for transfusion. This method of treatment is advocated for patients with widespread osseous metastasis, especially those with severe pain.
D000135:Acid Phosphatase / Q000097:blood; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology*; D011878:Radiotherapy / Q000009:adverse effects; D013739:Testosterone / Q000627:therapeutic use
D010761:Phosphorus Radioisotopes; D013739:Testosterone; D000135:Acid Phosphatase